No definition available.
Endpoint definition
↥Report an error or suggest an improvement for this endpoint codes
Endpoint definition steps |
FinnGen |
|---|---|
Phenotype data |
519972 |
1. Apply sex-specific ruleNone |
519972 |
2. Check conditionsNone |
519972 |
3. Check pre-conditions, main-only, mode, registry filtersRegistry filters:
2 out of 7 registries used, show all original rules. |
343 |
4. Check minimum number of eventsNone |
343 |
5. Include endpointsNone |
343 |
6. Filter based on genotype QC (FinnGen only) |
336 |
Control definitions (FinnGen only)
Controls for this endpoint are individuals that are not cases.
Extra metadata
- Level in the ICD hierarchy
- 3
- First used in FinnGen datafreeze
- DF2
- Parent code in ICD-10
- D30
- Name in latin
- Neoplasma benignum vesicae urinariae
Similar endpoints
↥List of similar endpoints to
Benign neoplasm: Bladder
based on the number of shared cases.
Similar with more cases:
- Benign neoplasm of urinary organs
- Benign neoplasms
- Neoplasms
- Any operation in hilmo
- Any event in hilmo or specialist outpatient
Similar with less cases:
None
Case counts by codes
↥
Summary Statistics
↥-FinRegistry-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | |||
| Whole population | 2475 | 947 | 1483 |
| Only index persons | 1772 | 757 | 1015 |
| Unadjusted period prevalence (%) | |||
| Whole population | 0.04 | 0.03 | 0.04 |
| Only index persons | 0.03 | 0.03 | 0.04 |
| Median age at first event (years) | |||
| Whole population | 63.13 | 60.11 | 64.96 |
| Only index persons | 61.04 | 57.95 | 63.34 |
-FinnGen-
Key figures
| All | Female | Male | |
|---|---|---|---|
| Number of individuals | 336 | 121 | 215 |
| Unadjusted period prevalence (%) | 0.08 | 0.04 | 0.10 |
| Median age at first event (years) | 62.76 | 56.32 | 66.38 |
-FinRegistry-
Age distribution of first events
-FinnGen-
Age distribution of first events
-FinRegistry-
Year distribution of first events
-FinnGen-
Year distribution of first events
-FinRegistry-
Cumulative Incidence Function
-FinnGen-
Cumulative Incidence Function
No data
CodeWAS
↥CodeWAS is a tool for exploring the associations between an endpoint and all of the medical codes and drug codes.
This is a new tool, please reach out using the contact form for feedback and improvement ideas.
First, a cohort is built by matching controls to the endpoint cases using year of birth and sex. Then, a Fisher test is done for all the medical codes and drug codes between the cases and controls of this cohort. Codes are reported in the table below if they have −log10(p-value) ≥ 6.
Matched cohort
- Matched cases
- 343
- Matched controls
- 3426
Code
Vocabulary
Description
Odds Ratio
-log10(p)
N matched cases
N matched controls
D30.3
ICD-10 Finland
Benign neoplasm: Bladder
+∞
307.7
284
*
KCD02
NOMESCO Finland
Transurethral resection of bladder
41.5
210.7
140
56
UKC02
NOMESCO Finland
Cystoscopy
21.2
174.4
264
467
D41.4
ICD-10 Finland
Neoplasm of uncertain or unknown behaviour: Bladder
34.7
145.3
98
39
KCD32
NOMESCO Finland
Cystoscopic destruction of tumour of bladder
58.3
87.6
50
10
C67.8
ICD-10 Finland
Malignant neoplasm: Overlapping lesion of bladder
20.1
86.3
71
44
C67.9
ICD-10 Finland
Malignant neoplasm: Bladder, unspecified
17.8
66.3
57
38
8120/3-C67.9
ICD-O-3
Transitional cell carcinoma, NOS, of bladder, NOS
19.0
62.8
52
32
R31
ICD-10 Finland
Unspecified haematuria
6.5
59.9
132
299
UKC05
NOMESCO Finland
Cystoscopy and bladder biopsy
26.4
59.1
42
18
C67.2
ICD-10 Finland
Malignant neoplasm: Lateral wall of bladder
20.5
56.9
45
25
KCD05
NOMESCO Finland
Excision of bladder lesion during urinary tract endoscopy with photodynamic diagnosis (PDD)
19.7
55.8
45
26
2233A
ICD-9 Finland
Benign neoplasm of kidney and other urinary organs, Bladder
+∞
39.3
37
*
1530
FHL
Urethrocystoscopy
9.7
30.3
37
42
22330
ICD-8 Finland
Benign neoplasm of kidney and other urinary organs, Bladder
+∞
29.6
28
*
7323
FHL
Electrosection of TU bladder wall change
101.2
26.1
28
*
D30.0
ICD-10 Finland
Benign neoplasm: Kidney
48.6
22.7
27
6
8120/1-C67.9
ICD-O-3
Urothelial papilloma, NOS, of bladder, NOS
200.3
18.7
19
*
7321
FHL
TU biopsy, coagulation or laser
50.0
16.2
19
*
WX320
NOMESCO Finland
Spinalanesthesy
2.7
15.5
118
563
KCB00
NOMESCO Finland
Biopsy of bladder
47.2
15.2
18
*
KH1AE
NOMESCO Finland
Urinary tract ultrasound examination
4.0
15.1
46
127
C67.1
ICD-10 Finland
Malignant neoplasm: Dome of bladder
67.2
11.7
13
*
J01EA01
ATC
trimethoprim; systemic
2.3
11.3
110
577
J01MA02
ATC
ciprofloxacin; systemic
2.1
10.3
167
1064
8130/1-C67.9
ICD-O-3
Papillary urothelial neoplasm of low malignant potential of bladder, NOS
41.3
10.0
12
*
KCW96
NOMESCO Finland
Other operations on bladder
20.7
9.9
14
7
C67.4
ICD-10 Finland
Malignant neoplasm: Posterior wall of bladder
56.6
9.7
11
*
JN3AD
NOMESCO Finland
Abdominal CT examination
2.8
9.7
54
216
WX408
NOMESCO Finland
General anesthesy, balanced
2.2
9.2
103
566
1888X
ICD-9 Finland
Malignant neoplasm of bladder, Other specified sites of bladder
37.7
9.1
11
*
R33
ICD-10 Finland
Retention of urine
2.5
8.1
56
248
JN3CD
NOMESCO Finland
Abdominal CT examination both without and with contrast
4.1
8.0
22
56
18899
ICD-8 Finland
Malignant neoplasm of bladder
46.0
7.7
9
*
TKC20
NOMESCO Finland
Catheterisation of bladder
2.7
7.7
43
172
KCW02
NOMESCO Finland
Lavation of bladder for coagulated blood
7.4
7.6
17
24
KH1CD
NOMESCO Finland
Very extensive urinary tract ultrasound examination
7.9
7.5
16
21
ZXE00
NOMESCO Finland
One hour or less
1.9
7.4
140
914
C67
ICD-10 Finland
Malignant neoplasm of bladder
20.5
7.2
10
5
N39.0
ICD-10 Finland
Urinary tract infection, site not specified
2.2
7.1
66
333
ZX136
NOMESCO Finland
Intravesicalis
10.3
7.1
13
13
C67.0
ICD-10 Finland
Malignant neoplasm: Trigone of bladder
10.3
7.1
13
13
KH1AD
NOMESCO Finland
CT of urinary organs
4.1
7.0
19
48
KC1EE
NOMESCO Finland
Ultrasound measurement of residual urine
2.1
7.0
74
394
8130/2-C67.9
ICD-O-3
Papillary urothelial carcinoma, non-invasive of bladder, NOS
9.6
6.8
13
14
N10
ICD-10 Finland
Acute tubulo-interstitial nephritis
2.2
6.8
61
304
KH1BT
NOMESCO Finland
Urinary tract cathetrisation with X-ray guidance
12.6
6.6
11
9
N39.3
ICD-10 Finland
Stress incontinence
3.2
6.5
26
86
UJD10
NOMESCO Finland
Esophagoscopy, gastroscopy and duodenoscopy
1.9
6.3
110
693
XKD00
NOMESCO Finland
Uroflowmetry
2.0
6.2
84
488
N13.3
ICD-10 Finland
Other and unspecified hydronephrosis
4.2
6.1
16
39
KBV02
NOMESCO Finland
Cystoscopic insertion of stent into ureter
5.7
6.1
16
29
LabWAS
↥OMOP Concept
People with measurements
Mean N measurements
Mean measured value
(ID) Name
N Cases
N Controls
OR
-log10(p)
cases
controls
cases
controls
unit
-log10(p)
N cases
N controls
174
1021
2.43
14.49
6.3
3.4
—
—
—
0
0
145
873
2.14
10.43
6.8
3.6
99.40
132.07
e6/l
0.15
124
679
112
619
2.20
9.93
4.3
2.7
3.20
4.12
e6/l
0.74
103
557
233
1792
1.93
7.36
8.8
4.7
3327.17
535.90
e6/l
—
6
30
179
1269
1.86
7.27
5.5
4.0
0.00
0.00
estimate
0.50
35
258
86
485
2.03
6.93
6.2
2.9
1.59
1.11
e6/l
0.40
59
279
179
1288
1.81
6.76
5.6
4.0
0.00
0.00
estimate
-0.00
33
228
176
1267
1.80
6.58
7.7
5.5
0.00
0.00
estimate
-0.00
33
236
123
799
1.84
6.43
7.1
3.4
0.40
0.55
e6/l
0.25
102
613
82
468
1.99
6.34
6.6
3.1
3.07
1.92
e6/l
0.36
55
265
117
755
1.83
6.22
2.3
2.0
2.61
3.20
mg/l
2.20
98
646
152
1082
1.72
5.65
3.2
2.7
146.13
148.88
ug/l
0.05
139
988
72
408
1.97
5.64
2.7
2.4
18.23
22.35
%
2.54
62
354
167
1227
1.70
5.48
3.2
2.5
—
—
—
0
0
74
430
1.92
5.37
2.6
2.4
2.34
2.29
g/l
0.31
69
393
183
1386
1.68
5.30
7.5
6.7
1.20
1.21
mmol/l
0.76
151
1170
78
472
1.84
4.97
2.6
2.3
11.87
12.66
umol/l
0.32
73
435
179
1392
1.59
4.35
20.0
16.5
1.38
1.36
inr
0.09
47
405
166
1272
1.59
4.27
5.8
6.0
1.21
1.21
mmol/l
0.47
149
1144
181
1439
1.54
3.81
7.5
6.4
11.12
12.10
umol/l
1.16
175
1358
197
1620
1.50
3.38
5.6
4.8
6.86
6.79
mmol/l
0.20
188
1515
21
93
2.34
3.09
2.2
4.5
—
2.46
—
0
12
182
1492
1.47
3.05
10.9
8.9
4.19
4.34
e9/l
0.38
160
1285
128
981
1.48
3.02
6.1
4.3
—
—
—
0
0
81
567
1.56
2.91
5.2
4.3
1.02
1.02
kg/l
0.33
18
87
7
14
5.07
2.74
1.7
2.4
11.86
16.29
%
—
7
14
10
29
3.52
2.71
1.9
2.1
—
—
—
0
0
6
10
6.08
2.70
1.2
1.1
—
—
—
0
0
31
170
1.90
2.68
1.3
1.4
—
—
—
0
0
89
651
1.49
2.59
2.9
2.3
—
—
—
0
0
16
68
2.42
2.59
1.3
1.6
0.22
0.04
iu/ml
—
6
18
33
191
1.80
2.43
5.6
3.2
1.39
1.72
mmol/l
0.17
25
141
32
184
1.81
2.41
2.3
1.6
—
—
—
0
0
149
1215
1.40
2.39
8.1
5.6
58.50
58.79
%
0.11
143
1130
145
1177
1.40
2.39
2.6
2.1
95.23
92.38
pmol/l
0.34
70
624
34
200
1.77
2.38
1.8
1.5
—
—
—
0
0
114
893
1.41
2.29
4.6
3.8
9.31
11.65
mg/mmol
0.35
74
562
121
960
1.40
2.25
3.7
3.2
1820.86
1695.97
ng/l
0.13
102
827
5
9
5.61
2.22
2.2
8.3
—
—
—
0
0
6
14
4.34
2.15
2.2
2.4
—
—
—
0
0
39
246
1.66
2.15
5.1
7.1
1.42
1.35
mmol/l
0.15
39
237
84
631
1.44
2.11
1.8
1.7
393.02
11004301.87
pmol/l
0.50
66
518
83
624
1.43
2.07
1.7
1.8
1019.46
1167.83
nmol/l
0.92
61
472
278
2552
1.46
2.05
24.6
16.4
23.11
25.79
mg/l
0.78
242
2087
51
349
1.54
2.02
5.6
6.9
0.32
1.13
mmol/l
0.90
40
281
287
2653
1.49
2.02
27.3
19.3
139.78
139.63
mmol/l
0.42
281
2570
287
2656
1.49
1.98
27.4
19.5
4.00
4.00
mmol/l
0.24
280
2571
148
1235
1.35
1.96
8.6
5.8
26.87
25.99
%
0.41
142
1145
210
1847
1.35
1.95
4.5
3.7
14.90
14.93
pmol/l
0.05
184
1623
8
27
3.00
1.94
3.4
1.3
—
—
—
0
0
50
344
1.53
1.94
1.9
1.7
—
—
—
0
0
95
740
1.39
1.94
3.5
2.9
383.77
9199.22
umol/l
3.92
79
628
106
843
1.37
1.90
3.2
2.4
52.80
61.12
u/l
0.73
101
777
156
1319
1.33
1.87
2.6
2.7
—
—
—
0
0
53
373
1.50
1.85
7.5
6.6
105.34
104.28
mmol/l
1.10
53
373
13
60
2.21
1.79
1.4
1.5
—
—
—
0
0
19
102
1.91
1.79
2.8
3.3
—
—
—
0
0
68
506
1.43
1.79
2.1
1.8
—
—
—
0
0
45
310
1.52
1.74
4.3
3.7
—
—
—
0
0
146
1232
1.32
1.74
6.5
4.7
34.08
34.89
g/l
1.00
138
1156
13
61
2.17
1.73
1.8
2.6
14.13
15.30
%
—
7
31
90
707
1.37
1.73
5.6
4.2
0.00
0.00
estimate
-0.00
32
229
13
62
2.14
1.67
2.2
2.2
122.29
125.32
g/l
—
7
44
113
927
1.32
1.63
4.0
3.3
2.36
2.35
mmol/l
0.77
97
803
228
2060
1.31
1.60
10.7
7.7
77.02
79.67
u/l
0.65
223
1904
13
64
2.07
1.55
1.7
1.6
—
—
—
0
0
48
344
1.46
1.55
1.9
1.8
—
—
—
0
0
20
116
1.77
1.52
2.4
1.7
—
—
—
0
0
136
1159
1.29
1.45
5.1
4.0
39.08
53.17
ng/l
0.87
104
892
13
66
2.01
1.45
1.4
1.6
—
—
—
0
0
214
1932
1.28
1.43
5.9
4.1
15.25
13.48
mm/h
0.69
199
1745
6
23
2.63
1.37
1.0
1.1
—
—
—
0
0
6
24
2.52
1.30
1.0
1.1
—
—
—
0
0
255
2367
1.30
1.30
7.6
6.5
41.73
40.88
mmol/mol
0.68
237
2158
(3020427) Coagulation factor X inhibitor [Units/volume] in Platelet poor plasma by Coagulation assay
16
92
1.77
1.27
2.4
2.3
0.36
0.39
u/ml
—
7
49
8
36
2.25
1.25
1.6
1.4
—
—
—
0
0
8
37
2.19
1.22
1.5
1.5
—
—
—
0
0
5
19
2.65
1.22
1.4
1.2
—
—
—
0
0
5
19
2.65
1.22
1.6
1.1
—
—
—
0
0
5
19
2.65
1.22
1.4
1.2
—
—
—
0
0
5
19
2.65
1.22
1.8
1.4
—
—
—
0
0
6
128
0.46
1.19
1.2
1.8
—
—
—
0
0
118
1012
1.25
1.16
2.8
2.3
76.08
76.44
nmol/l
0.04
105
873
88
729
1.28
1.15
1.9
1.6
21.17
19.89
nmol/l
0.31
73
601
248
2308
1.26
1.15
5.7
4.5
2.09
1.97
mu/l
0.43
226
2038
71
572
1.30
1.15
5.4
3.8
225.69
222.17
ng/l
0.01
62
476
173
1549
1.23
1.14
4.6
3.2
58.91
54.25
u/l
0.26
163
1419
290
2757
1.33
1.10
35.7
24.0
239.01
238.83
e9/l
0.01
284
2672
290
2758
1.33
1.09
35.6
24.0
4.38
4.44
e12/l
0.98
284
2658
290
2758
1.33
1.09
35.7
24.1
39.79
39.64
%
0.17
266
2563
5
21
2.40
1.09
1.2
1.1
—
—
—
0
0
29
203
1.47
1.09
4.3
2.8
53.90
61.07
ml/min/173m2
—
10
85
13
75
1.76
1.04
1.9
1.6
—
—
—
0
0
7
34
2.08
1.03
1.0
1.4
—
—
—
0
0
61
490
1.30
1.01
1.3
1.2
0.55
1.65
u/ml
1.47
14
126
32
232
1.42
1.01
2.5
2.0
375.48
381.90
nmol/l
0.06
27
212
7
35
2.02
1.00
2.9
1.6
13.16
16.58
ug/l
—
7
35
5
23
2.19
0.98
2.2
1.3
—
—
—
0
0
0
29
0.00
0.98
0.0
2.1
—
—
—
0
0
7
36
1.96
0.97
1.3
1.5
—
—
—
0
0
7
36
1.96
0.97
1.3
1.5
—
—
—
0
0
7
36
1.96
0.97
1.1
1.5
—
—
—
0
0
7
37
1.91
0.94
1.3
1.5
—
—
—
0
0
7
37
1.91
0.94
1.3
1.5
—
—
—
0
0
7
37
1.91
0.94
1.3
1.5
—
—
—
0
0
40
306
1.35
0.94
1.4
1.4
—
—
—
0
0
9
52
1.75
0.93
1.0
1.4
—
—
—
0
0
47
370
1.31
0.91
5.0
4.9
32.00
32.22
%
0.04
29
242
143
1279
1.20
0.90
6.0
5.5
2.23
3.05
ug/l
1.14
129
1129
250
2355
1.22
0.89
4.6
4.3
1.39
1.26
mmol/l
1.82
222
2114
8
43
1.88
0.88
1.6
1.5
—
—
—
0
0
6
30
2.01
0.87
3.7
2.9
—
—
—
0
0
8
45
1.79
0.84
3.3
3.7
53.00
58.80
%
—
8
45
8
46
1.75
0.83
1.6
1.5
—
—
—
0
0
19
130
1.49
0.82
2.4
1.8
—
—
—
0
0
45
358
1.29
0.82
1.4
1.3
34.70
12.91
u/ml
0.47
20
124
0
28
0.00
0.76
0.0
1.7
—
—
—
0
0
0
28
0.00
0.76
0.0
1.7
—
—
—
0
0
0
28
0.00
0.76
0.0
1.7
—
—
—
0
0
41
328
1.28
0.73
3.7
4.4
3.96
45.98
ug/l
1.10
33
281
5
25
2.01
0.73
8.2
3.2
64.00
79.07
u/ml
—
5
25
9
56
1.62
0.73
1.8
1.3
—
—
—
0
0
7
40
1.76
0.71
1.3
1.0
—
—
—
0
0
258
2462
1.19
0.68
5.1
4.8
4.38
4.44
mmol/l
0.37
230
2240
17
119
1.45
0.68
1.9
2.9
3.42
3.58
g/l
0.23
17
106
17
119
1.45
0.68
1.9
2.9
7.59
7.44
g/l
0.13
17
106
17
119
1.45
0.68
1.9
2.9
—
—
—
0
0
67
573
1.21
0.67
1.8
1.7
1.00
1.44
mg/l
1.53
52
450
5
28
1.79
0.66
2.2
1.4
—
—
—
0
0
5
28
1.79
0.66
1.4
1.4
—
—
—
0
0
277
2664
1.20
0.65
14.6
11.1
25.25
25.21
u/l
0.02
266
2546
46
380
1.24
0.64
1.2
1.3
21.84
37.16
iu/ml
1.20
16
128
255
2439
1.17
0.62
5.2
4.7
1.37
1.43
mmol/l
1.50
227
2201
34
273
1.27
0.60
2.5
2.5
5.45
8.56
ug/l
0.83
26
239
10
64
1.58
0.59
1.9
1.5
—
—
—
0
0
10
64
1.58
0.59
1.2
1.3
—
—
—
0
0
13
89
1.48
0.58
1.1
1.2
—
—
—
0
0
42
348
1.23
0.58
10.3
7.8
—
—
—
0
0
262
2518
1.17
0.56
5.5
5.4
2.56
2.59
mmol/l
0.25
233
2269
257
2467
1.16
0.56
5.8
5.0
6.30
6.08
mmol/l
1.70
232
2217
6
38
1.59
0.54
1.7
1.6
—
—
—
0
0
6
39
1.55
0.53
1.0
1.2
—
—
—
0
0
20
153
1.32
0.51
1.6
1.9
—
—
—
0
0
249
2392
1.15
0.50
24.2
15.6
72.20
75.42
ml/min/173m2
1.54
219
1964
15
110
1.38
0.49
1.1
1.0
—
—
—
0
0
11
76
1.46
0.48
1.2
1.6
—
—
—
0
0
7
50
1.41
0.45
2.0
1.4
—
—
—
0
0
75
673
1.14
0.44
1.8
1.7
1.37
1.31
mmol/l
0.34
68
549
5
33
1.52
0.41
1.2
1.1
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
16
0.00
0.41
0.0
1.8
—
—
—
0
0
0
17
0.00
0.40
0.0
1.8
—
—
—
0
0
0
17
0.00
0.40
0.0
1.8
—
—
—
0
0
0
17
0.00
0.40
0.0
1.7
—
—
—
0
0
5
34
1.48
0.40
2.2
1.4
—
—
—
0
0
0
18
0.00
0.40
0.0
1.2
—
—
—
0
0
9
71
1.27
0.36
1.6
1.3
—
—
—
0
0
6
43
1.40
0.35
1.5
1.4
—
—
—
0
0
14
109
1.29
0.34
2.1
3.0
2.62
3.01
g/l
1.07
14
96
11
83
1.33
0.32
2.3
3.5
0.00
0.00
g/l
-0.00
11
75
21
248
0.84
0.29
1.6
1.3
—
—
—
0
0
11
85
1.30
0.28
2.3
3.4
0.00
0.00
g/l
-0.00
11
76
8
64
1.25
0.27
1.9
1.5
—
—
—
0
0
11
139
0.78
0.27
1.3
1.3
—
45.81
—
0
8
8
65
1.23
0.27
1.4
1.3
—
—
—
0
0
0
10
0.00
0.21
0.0
1.0
—
—
—
0
0
0
11
0.00
0.21
0.0
1.2
—
168.15
—
0
11
0
11
0.00
0.21
0.0
1.5
—
8.66
—
0
11
0
12
0.00
0.21
0.0
2.3
—
13.85
—
0
12
6
48
1.25
0.20
2.0
1.6
—
—
—
0
0
0
14
0.00
0.20
0.0
3.8
—
—
—
0
0
0
14
0.00
0.20
0.0
1.2
—
156.38
—
0
14
0
14
0.00
0.20
0.0
3.8
—
—
—
0
0
69
732
0.93
0.19
4.2
3.2
0.76
0.81
ug/l
0.17
53
523
11
90
1.23
0.19
2.3
3.3
0.00
0.00
g/l
-0.00
11
81
52
557
0.92
0.19
4.3
3.3
2.49
2.45
mmol/l
1.37
44
489
7
60
1.17
0.18
1.7
2.0
—
—
—
0
0
11
128
0.85
0.14
3.4
3.1
11.09
2296.26
u/ml
1.01
11
111
8
100
0.79
0.13
1.1
1.3
—
—
—
0
0
11
95
1.16
0.11
2.4
3.2
38.49
37.51
g/l
0.24
11
82
15
140
1.07
0.04
1.7
1.8
—
—
—
0
0
11
102
1.08
0.03
2.3
3.2
0.07
0.83
g/l
1.65
11
89
102
1023
0.99
0.00
5.5
4.7
19.91
21.49
%
0.70
55
532
7
72
0.97
0.00
1.0
1.2
—
—
—
0
0
7
71
0.98
0.00
1.0
1.2
—
—
—
0
0
(40770918) von Willebrand factor (vWf).activity actual/normal in Platelet poor plasma by Immunoassay
0
6
0.00
0.00
0.0
5.5
—
119.00
—
0
6
5
51
0.98
-0.00
1.4
1.9
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.3
—
1.26
—
0
8
0
8
0.00
-0.00
0.0
1.4
—
—
—
0
0
6
62
0.97
-0.00
1.2
1.4
—
—
—
0
0
0
8
0.00
-0.00
0.0
1.6
—
7.72
—
0
8
6
62
0.97
-0.00
1.2
1.4
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.2
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
0
5
0.00
-0.00
0.0
1.0
—
—
—
0
0
Mortality – FinRegistry
↥Association
Association between endpoint CD2_BENIGN_BLADDER and mortality.
Females
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BLADDER | 1.365 [1.11, 1.68] | 0.004 |
| Birth year | 0.991 [0.98, 1.0] | 0.048 |
During the follow-up period (1.1.1998 — 31.12.2019), 171 out of 564 females with CD2_BENIGN_BLADDER died.
Males
| Parameter | HR [95% CI] | p-value |
|---|---|---|
| CD2_BENIGN_BLADDER | 1.415 [1.17, 1.7] | < 0.001 |
| Birth year | 0.988 [0.98, 1.0] | 0.011 |
During the follow-up period (1.1.1998 — 31.12.2019), 343 out of 846 males with CD2_BENIGN_BLADDER died.
Mortality risk
Mortality risk for people of age
years, who have CD2_BENIGN_BLADDER.| N-year risk | Females | Males |
|---|---|---|
| 1 | 0.114% | 0.309% |
| 5 | 0.766% | 1.871% |
| 10 | 1.776% | 4.391% |
| 15 | 3.311% | 8.048% |
| 20 | 5.832% | 13.67% |
Relationships between endpoints
↥Index endpoint: CD2_BENIGN_BLADDER – Benign neoplasm: Bladder
GWS hits: -
Endpoint
Case Overlap
Survival Analysis
Genetic Correlations
Genetic Signals
N (Jaccard index)
HR [CI]
rg [CI]
Hits
Coloc Hits
FinRegistry
FinnGen
FinRegistry
FinnGen
FinnGen
Loading data